Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nomacopan - Akari Therapeutics

Drug Profile

Nomacopan - Akari Therapeutics

Alternative Names: Coversin; EV 576; long-acting PAS-nomacopan; PAS-coversin; PAS-nomacopan; rEV 576; rVA576

Latest Information Update: 21 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evolutec
  • Developer Akari Therapeutics; Evolutec; US Army Institute of Surgical Research
  • Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Antithrombotics; Antivirals; Eye disorder therapies; Recombinant proteins; Skin disorder therapies
  • Mechanism of Action Complement C5a inhibitors; Leukotriene B4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Thrombotic microangiopathy; Guillain-Barre syndrome; Bullous pemphigoid; Thrombotic microangiopathies
  • New Molecular Entity Yes
  • Available For Licensing Yes - Eye disorders

Highest Development Phases

  • Phase III Haemolytic uraemic syndrome; Thrombotic microangiopathy
  • Phase I/II COVID-19 pneumonia; Keratoconjunctivitis
  • Preclinical Asthma; Dry age-related macular degeneration; Haemorrhagic shock; Subarachnoid haemorrhage; Traumatic brain injuries; Uveitis; Wet age-related macular degeneration
  • No development reported Guillain-Barre syndrome; Myasthenia gravis; Rheumatoid arthritis; Sjogren's syndrome
  • Discontinued Autoimmune disorders; Bullous pemphigoid; Inflammation; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 16 Nov 2023 Akari Therapeutics plans to file an IND application with the US FDA for Dry age-related macular degeneration in 2024
  • 29 Sep 2023 Akari Therapeutics plans a Type C meeting with the US FDA for Thrombotic microangiopathy (In adults) in November 2023
  • 28 Sep 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-19 pneumonia in Brazil (SC, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top